
---
title: '甘李药业：甘精胰岛素原料药和注射液获巴拉圭注册批件'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=7800'
author: 证券时报网
comments: false
date: Fri, 20 Aug 2021 17:51:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=7800'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SS603087" style="color: #2f67d1;text-decoration: none;" code="603087" target="_blank">甘李药业</a>(603087)8月20日晚间公告，近日，公司收到巴拉圭药监局（DNVS）核准签发的甘精胰岛素原料药和注射液的注册批件。甘精胰岛素药品注册的获批，表明<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SS603087" style="color: #2f67d1;text-decoration: none;" code="603087" target="_blank">甘李药业</a>具备向巴拉圭销售甘精胰岛素注射液的许可。</p>
                  
</div>
            